WHY DO MEDICAL SOLUTIONS CREATE SO MANY PROBLEMS? WE THINK WE CAN DO BETTER.
Our relentless team of innovative scientists has developed a new Fixed Dose Combination product that would allow people to live life unencumbered by side effects, free to pursue their goals and dreams. And, perhaps one day, wonder what a side effect even is.
Introducing ExultaTM , a new pharmaceutical offering for the treatment and PREVENTION of a number of new and broad indications.
Sen-Jam has submitted numerous patents, defined the market potential and, armed with the latest international scientific research, is pursuing Exulta TM for the reduction and/or prevention of side effects associated with the common cold, opioid withdrawal, vaccine administration and alcohol consumption (a.k.a. hangover).
After completing our pre-IND meeting with the FDA in Q4 2016, Sen-Jam has obtained an IND in Q2 2017 with Phase 1 studies beginning Q4 2017. Exulta TM can prove efficacy and will be the first OTC FDA approved product of its kind. Sen-Jam Pharmaceutical anticipates using the 505 (b) 2 pathway for FDA approval with NDA submitted Q4 2019.